IL13Ra2-binding chimeric antigen receptors
US12083148B2 · kind B2 · utility
0Cited by
0References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 22, 2018 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | Sep 17, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N5/0636
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill IL13Ra2-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with an IL13Ra2-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.